173 completed, 56 terminated, 35 unknown, 31 active not recruiting. 208 Phase 2, 117 Phase 1, 23 Phase 3, 10 Not applicable, 10 Phase 4.
Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Ropeginterferon alfa-2b (P1101) - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-13 | 2026-10-13 |
| Dasatinib for HIV-1 Reservoir Reduction Dasatinib, Placebo - HIV Infections | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 14 | 2026-05-08 | 2026-10-27 |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| Senolytics for Secondary Progressive MS Dasatinib and quercetin - Multiple Sclerosis (MS) Secondary Progressive | Phase 1 | Not yet recruiting | Ohio State University | 30 | 2026-01-15 | 2025-12-08 |
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy TKIs - Chronic Myelogenous Leukemia - Chronic Phase | Recruiting | Novartis Pharmaceuticals | 1000 | 2025-12-17 | 2026-07-20 | |
| Improving Physical Ability and Cellular Senescence Elimination in HIV Dasatinib, Quercetin, Placebo - Dasatinib - HIV, Frailty | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 82 | 2025-12-04 | 2026-09-15 |
| HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Dasatinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2025-10-01 | 2025-09-16 |
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| Bioequivalence Studies of Dasatinib 100 Mg Dasatinib 100 MG - Myeloma Multiple | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 46 | 2025-09-01 | 2025-02-12 |
| Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease Biospecimen Collection, Dasatinib, Fisetin - Glioma | Early Phase 1 | Recruiting | Mayo Clinic | 30 | 2025-08-12 | 2026-10-01 |
| Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline | Phase 2 | Completed | Washington University School of Medicine | 23 | 2025-07-28 | 2026-08-19 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Newly-diagnosed Pediatric T-cell ALL Protocol Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 610 | 2025-03-11 | 2025-08-26 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies KQB198, Dasatinib - Hematologic Malignancies, Adult | Phase 1 | Active not recruiting | Kumquat Biosciences Inc. | 13 | 2024-12-09 | 2026-03-25 |
| Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Dasatinib Pill, Ketoconazole Pill - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2024-11-01 | 2022-12-06 |
Showing 20 of 345. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (66) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (52) · Leukemia, Myeloid, Chronic-Phase (35) · Leukemia (30) · Breast Neoplasms (18) · Leukemia, Myeloid, Acute (18) · Recurrence (17) · Prostatic Neoplasms (14) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Blast Crisis (12) · Neoplasm Metastasis (12) · Burkitt Lymphoma (11) · Carcinoma, Non-Small-Cell Lung (11) · Multiple Myeloma (11) · Pancreatic Neoplasms (10)
Bristol-Myers Squibb (57) · National Cancer Institute (NCI) (33) · M.D. Anderson Cancer Center (26) · St. Jude Children's Research Hospital (9) · Duke University (6) · Mayo Clinic (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Memorial Sloan Kettering Cancer Center (5) · OHSU Knight Cancer Institute (5) · City of Hope Medical Center (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Jonsson Comprehensive Cancer Center (4) · Novartis Pharmaceuticals (4) · Washington University School of Medicine (4) · Alliance for Clinical Trials in Oncology (3)
United States (230) · France (44) · Italy (42) · Canada (38) · Germany (37) · China (33) · Spain (33) · United Kingdom (27) · Australia (24) · South Korea (20) · Netherlands (19) · Finland (18) · Belgium (17) · Norway (17) · Austria (16)
Abhinav Deol, M.D. (2) · Charles Sawyers, MD (2) · David S. Hong, MD (2) · Ehab Atallah, MD (2) · Eric Lenze, MD (2) · Huachao Zhu (2) · Jianxiang Wang, Dr. (2) · Juan Ren (2) · Nicolas Musi, MD (2) · Noah Hahn, M.D. (2) · Pengcheng He (2) · Philip Amrein, MD (2) · Stacy Moulder, MD (2)
PMID 41671463, PMID 16775234, PMID 24357015, PMID 24727329, PMID 29720733, PMID 33242441, PMID 34366147, PMID 34687726, PMID 39121442, PMID 40009460, PMID 12011123, PMID 16960978, PMID 17317857, PMID 19369231, PMID 19536906, PMID 20131302, PMID 20466853, PMID 20525995, PMID 20563869, PMID 21508120, PMID 21623279, PMID 21623761, PMID 21931113, PMID 21976132, PMID 22160483, PMID 22645182, PMID 22915637, PMID 23328954, PMID 23380743, PMID 23620574, PMID 23652277, PMID 23676418, PMID 23715577, PMID 23980906, PMID 24128713, PMID 24173967, PMID 24211163, PMID 24311723, PMID 24457377, PMID 24569263, PMID 24722180, PMID 24788563, PMID 24970932, PMID 25082346, PMID 25087182, PMID 25170013, PMID 25501110, PMID 25758746, PMID 25761894, PMID 26118315
P30CA016672 (6), U10CA180888 (5), 2008 (4), U10CA031946 (4), U10CA032102 (4), U10CA180820 (4), P30CA033572 (3), 2023 (2), N01CM00071 (2), N01CM62201 (2), N01CM62202 (2), P30CA008748 (2), P30CA014599 (2), P30CA015704 (2), P30CA068485 (2)